GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$62.10
-1.64 (-2.57%)
Financial Highlights (FY 2026)
Revenue
171.85M
Net Income
-476,824,869
Gross Margin
48.5%
Profit Margin
-277.5%
Rev Growth
+38.4%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.5% 48.5% 65.8% 65.8%
Operating Margin -382.0% -343.8% 9.2% 8.6%
Profit Margin -277.5% -263.6% 7.6% 7.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 171.85M 124.20M 2.02B 1.78B
Gross Profit 83.28M 60.19M 1.33B 1.17B
Operating Income -656,436,205 -426,965,805 184.76M 152.85M
Net Income -476,824,869 -310,141,202 154.03M 135.92M
Gross Margin 48.5% 48.5% 65.8% 65.8%
Operating Margin -382.0% -343.8% 9.2% 8.6%
Profit Margin -277.5% -263.6% 7.6% 7.7%
Rev Growth +38.4% +38.4% +15.5% +5.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.78B 1.62B
Total Equity 1.86B 2.14B
D/E Ratio 0.96 0.76
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -500,085,666 -343,341,318 214.07M 192.49M
Free Cash Flow 137.52M 156.47M